BACKGROUND Metformin, an antidiabetic drug, decreases the incidence of various cancers
in diabetic patients. Metformin‐induced inhibition of cancer cell proliferation has been …

Background Metformin has been associated with reduced cancer risk. The mechanisms
underlying this cancer protective effect remain unknown. Methods “Window of opportunity” …

Background Endometrial cancer is one of the most common gynecological cancers, which is
frequently preceded by atypical endometrial hyperplasia, a premalignant lesion. Metformin …

Purpose: Endometrioid endometrial cancer is strongly associated with obesity and insulin
resistance. Metformin, an insulin sensitizer, reduces endometrial tumor growth in vitro …

OBJECTIVES: Obesity and diabetes are strong risk factors that drive the development of type
I endometrial cancers. Recent epidemiological evidence suggests that metformin may lower …

We conducted a preoperative window study of metformin in endometrial cancer (EC)
patients and evaluated its antiproliferative, molecular and metabolic effects. Twenty obese …

Objective Preclinical evidence suggests that metformin exhibits anti-tumorigenic effects in
endometrial cancer. We sought to investigate the association of metformin on endometrial …

Objective Metformin reduces cancer incidence and improves overall survival in diabetic
patients. In preclinical studies, metformin decreases endometrial cancer (EC) cell growth by …

Obesity, diabetes and insulin resistance are marked risk factors that promote the
development of type I endometrial cancer. Previous studies have demonstrated that insulin …

Endometrial cancer is the most common gynecologic malignancy in developed countries. Its
increasing incidence is thought to be related in part to the rise of metabolic syndrome, which …